December 10, 2019. Yesterday the Financial Times featured an article on Organoid Innovation:
“Organoids have become one of the fastest growing fields in biomedical research over the past decade”
Prof Clevers: “We set up a non-profit foundation called Hubrecht Organoid Technology [HUB], which holds my lab’s patents. In addition to carrying out research, HUB offers licences for drug screening and access to organoids in its biobanks for pre-clinical drug discovery and validation.”
Pharmaceutical companies are using organoids derived from specific tumours to screen potential cancer drugs. A wide range of tissues are available for applications ranging from drug discovery to personalised medicine.